Format

Send to

Choose Destination
Rev Med Chil. 2018 Jul;146(7):846-853. doi: 10.4067/s0034-98872018000700846.

[Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia].

[Article in Spanish]

Author information

1
Servicio de Hematología, Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, México.
2
Laboratorio de Biología Molecular, Servicio de Hematología, Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, México.
3
Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, Secretaria de Salud, Ciudad de México, México.

Abstract

BACKGROUND:

Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest.

AIM:

To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse.

MATERIAL AND METHODS:

We included 123 patients treated with metformin and without metformin. The dose used was 850 mg PO at 8 h intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test.

RESULTS:

The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p = 0.006).

CONCLUSIONS:

The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.

PMID:
30534883
DOI:
10.4067/s0034-98872018000700846
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online
Loading ...
Support Center